Compare
Lyell Immunopharma, Inc. vs Neonc Technologies Holdings, Inc. vs Impact Biomedical Inc. vs Altimmune, Inc.
| Latest fiscal year | Lyell Immunopharma, Inc. LYEL | Neonc Technologies Holdings, Inc. NTHI | Impact Biomedical Inc. IBO | Altimmune, Inc. ALT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $36.0K | $40.0K | $32.0K | $41.0K |
| Revenue growth (YoY) | -41.0% | -51.8% | n/a | +105.0% |
| Gross margin | n/a | n/a | n/m (computed) | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$274.45M | -$62.15M | -$11.84M | -$88.09M |
| EPS (Diluted) | -$16.06 | -$3.20 | -$0.38 | -$1.00 |
| Operating cash flow | -$150.02M | -$20.36M | -$1.89M | -$67.53M |
| Free cash flow | -$150.80M | -$20.86M | n/a | -$67.55M |
| Cash & equivalents | $60.18M | $58.7K | $3.0K | $43.76M |
| Total assets | $340.05M | $2.82M | $17.41M | $279.93M |
| Total liabilities | $91.85M | $20.33M | $1.85M | $55.04M |
| Shareholders' equity | $248.20M | -$17.51M | $12.61M | $224.89M |
| Return on year-end equity | -110.6% | n/a | -93.9% | -39.2% |
| Shares outstanding | 21.25M | 21.99M | 104.62M | 110.88M |
Revenue, most recent five fiscal years
| Fiscal year | Lyell Immunopharma, Inc. | Neonc Technologies Holdings, Inc. | Impact Biomedical Inc. | Altimmune, Inc. |
|---|---|---|---|---|
| Latest | $36.0K Ended 2025-12-31 | $40.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $41.0K Ended 2025-12-31 |
| 1 year earlier | $61.0K Ended 2024-12-31 | $83.0K Ended 2024-12-31 | n/a | $20.0K Ended 2024-12-31 |
| 2 years earlier | $130.0K Ended 2023-12-31 | n/a | n/a | $426.0K Ended 2023-12-31 |
| 3 years earlier | $84.68M Ended 2022-12-31 | n/a | $50.0K Ended 2022-12-31 | -$68.0K Ended 2022-12-31 |
| 4 years earlier | $10.65M Ended 2021-12-31 | n/a | n/a | $4.41M Ended 2021-12-31 |